TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$86.3 Million

Sera Prognostics, Inc.

Initial Public Offering

Bookrunner, July 2021

Sera Prognostics, Inc. (“Sera Prognostics” or the “Company”) is a women’s health company leveraging its proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Sera’s vision is to delivery pivotal and actionable information to pregnant women, their physicians and healthcare payers to improve maternal and neonatal health and reduce healthcare costs.

More Like This

Mar 2022
$79.4 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Nov 2021
$116.3 Million

Initial Public Offering

Bookrunner

View Details
Nov 2021
$500.3 Million

Initial Public Offering

Bookrunner

View Details